Immuneering Corp IMRX
We take great care to ensure that the data presented and summarized in this overview for Immuneering Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMRX
View all-
Vanguard Group Inc Valley Forge, PA1.06MShares$4.24 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0808KShares$3.24 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD659KShares$2.64 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$2.14 Million0.0% of portfolio
-
Morgan Stanley New York, NY467KShares$1.87 Million0.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$982,4501.61% of portfolio
-
Geode Capital Management, LLC Boston, MA226KShares$905,5260.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL84KShares$336,6790.0% of portfolio
-
Manufacturers Life Insurance Company, The Toronto, A682.7KShares$331,4940.0% of portfolio
-
State Street Corp Boston, MA78.5KShares$314,9250.0% of portfolio
Latest Institutional Activity in IMRX
Top Purchases
Top Sells
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Insider Transactions at IMRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 02
2025
|
Diana Hausman Director |
BUY
Open market or private purchase
|
Indirect |
3,000
+50.0%
|
$9,000
$3.62 P/Share
|
|
Jul 02
2025
|
Diana Hausman Director |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$7,500
$3.6 P/Share
|
|
Jul 02
2025
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
700
+6.12%
|
$2,100
$3.57 P/Share
|
|
Jul 02
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
7,015
+0.3%
|
$21,045
$3.53 P/Share
|
|
Jul 01
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,985
+0.13%
|
$8,955
$3.38 P/Share
|
|
Jun 27
2025
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
9,500
+15.23%
|
$28,500
$3.66 P/Share
|
|
Jun 23
2025
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
6,007
+1.64%
|
$12,014
$2.43 P/Share
|
|
Jun 20
2025
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
7,415
+2.06%
|
$14,830
$2.7 P/Share
|
|
Jun 20
2025
|
Harold Eugene Brakewood Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
1,900
+24.68%
|
$3,800
$2.53 P/Share
|
|
Jun 18
2025
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+15.45%
|
$50,000
$2.53 P/Share
|
|
Jun 18
2025
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
21,000
+0.9%
|
$42,000
$2.39 P/Share
|
|
Jun 17
2025
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
40,485
+48.27%
|
$80,970
$2.21 P/Share
|
|
Sep 15
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,458
+25.93%
|
$4,458
$1.62 P/Share
|
|
Apr 01
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
400,000
-1.52%
|
$1,200,000
$3.01 P/Share
|
|
Mar 22
2024
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
2,900
+50.0%
|
$5,800
$2.55 P/Share
|
|
Mar 22
2024
|
Harold Eugene Brakewood Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
3,900
+50.0%
|
$7,800
$2.57 P/Share
|
|
Mar 22
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+18.28%
|
$50,000
$2.55 P/Share
|
|
Mar 22
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
393
+4.53%
|
$786
$2.55 P/Share
|
|
Mar 21
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
1,107
+12.31%
|
$2,214
$2.72 P/Share
|
|
Mar 20
2024
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,818
+27.57%
|
$7,636
$2.88 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 128K shares |
|---|---|
| Grant, award, or other acquisition | 4.46K shares |